223 related articles for article (PubMed ID: 1775613)
1. Nicotine potentiates the behavioral effects of haloperidol.
Emerich DF; Norman AB; Sanberg PR
Psychopharmacol Bull; 1991; 27(3):385-90. PubMed ID: 1775613
[TBL] [Abstract][Full Text] [Related]
2. Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity.
Emerich DF; Zanol MD; Norman AB; McConville BJ; Sanberg PR
Pharmacol Biochem Behav; 1991 Apr; 38(4):875-80. PubMed ID: 1871200
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of haloperidol-induced catalepsy by nicotine: an investigation of possible mechanisms.
Boye SM; Clarke PB
Can J Physiol Pharmacol; 2000 Nov; 78(11):882-91. PubMed ID: 11100936
[TBL] [Abstract][Full Text] [Related]
4. Individual phenotype predicts nicotine-haloperidol interaction in catalepsy: possible implication for the therapeutic efficacy of nicotine in Tourette's syndrome.
Boye SM
Behav Brain Res; 2013 Jan; 236(1):30-34. PubMed ID: 22947904
[TBL] [Abstract][Full Text] [Related]
5. Nicotine potentiation of haloperidol-induced catalepsy: striatal mechanisms.
Sanberg PR; Emerich DF; el-Etri MM; Shipley MT; Zanol MD; Cahill DW; Norman AB
Pharmacol Biochem Behav; 1993 Oct; 46(2):303-7. PubMed ID: 8265684
[TBL] [Abstract][Full Text] [Related]
6. Effects of buspirone on dopamine dependent behaviours in rats.
Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
[TBL] [Abstract][Full Text] [Related]
7. Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease.
Trevitt J; Vallance C; Harris A; Goode T
Pharmacol Biochem Behav; 2009 May; 92(3):521-7. PubMed ID: 19463269
[TBL] [Abstract][Full Text] [Related]
8. Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome.
Sanberg PR; McConville BJ; Fogelson HM; Manderscheid PZ; Parker KW; Blythe MM; Klykylo WM; Norman AB
Biomed Pharmacother; 1989; 43(1):19-23. PubMed ID: 2730949
[TBL] [Abstract][Full Text] [Related]
9. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents.
Khisti RT; Deshpande LS; Chopde CT
Psychopharmacology (Berl); 2002 May; 161(2):120-8. PubMed ID: 11981591
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats.
Agovic MS; Yablonsky-Alter E; Lidsky TI; Banerjee SP
Eur J Pharmacol; 2008 Jun; 587(1-3):181-6. PubMed ID: 18457824
[TBL] [Abstract][Full Text] [Related]
11. Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol.
Ali O; Haleem DJ; Saify ZS; Kamil N; Obaid R; Ahmed SW
Pak J Pharm Sci; 2005 Apr; 18(2):23-8. PubMed ID: 16431394
[TBL] [Abstract][Full Text] [Related]
12. Effect of piracetam, a cyclic GABA analogue, on haloperidol-induced catalepsy in the rat.
Balsara JJ; Bapat TR; Chandorkar AG
Indian J Physiol Pharmacol; 1980; 24(3):227-32. PubMed ID: 7193183
[TBL] [Abstract][Full Text] [Related]
13. Effects of dextromethorphan on dopamine dependent behaviours in rats.
Gaikwad RV; Gaonkar RK; Jadhav SA; Thorat VM; Jadhav JH; Balsara JJ
Indian J Exp Biol; 2007 Aug; 45(8):712-9. PubMed ID: 17877148
[TBL] [Abstract][Full Text] [Related]
14. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
15. Serotonergic involvement in haloperidol-induced catalepsy.
Neal-Beliveau BS; Joyce JN; Lucki I
J Pharmacol Exp Ther; 1993 Apr; 265(1):207-17. PubMed ID: 8386235
[TBL] [Abstract][Full Text] [Related]
16. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M
Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647
[TBL] [Abstract][Full Text] [Related]
17. Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice.
Chinen CC; Frussa-Filho R
Neuropsychopharmacology; 1999 Nov; 21(5):670-8. PubMed ID: 10516963
[TBL] [Abstract][Full Text] [Related]
18. Influence of dopamine agonists and an opiate antagonist on agaricus-induced catalepsy, as tested by a new method.
Sukul NC; Klemm WR
Arch Int Pharmacodyn Ther; 1988; 295():40-51. PubMed ID: 2907723
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of haloperidol catalepsy by microinjections of nicotine into the striatum or pons in rats.
Elazar Z; Paz M
Life Sci; 1999; 64(13):1117-25. PubMed ID: 10210274
[TBL] [Abstract][Full Text] [Related]
20. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
Zharkovskiĭ AM; Matvienko OA; Nurk AM
Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
